Merck wins Alabama Vioxx case

Share this article:
Alabama state court jurors ruled in Merck’s favor Friday, rejecting the claims of a plaintiff who blamed the drugmaker’s withdrawn painkiller Vioxx for his heart attack in 2001. The verdict marks the second time in three days that a jury has sided with Merck in a trial over Vioxx. A federal court in New Orleans ruled in favor of Merck Wednesday. “Juries continue to determine that Merck acted responsibly in its research of Vioxx and provided the appropriate information about Vioxx to patients and the medical community,” Merck EVP and general counsel Kenneth Frazier said in a statement. Attorneys for the plaintiff in the latest case, 57-year-old Chelsea, Ala. resident Gary Albright, told jurors he should receive as much as $5.75 million in his lawsuit filed last year. But jurors speaking with attorneys and reporters in the courtroom after the verdict said Albright had too many health problems before his heart attack to blame Vioxx, according to a report at WSJ.com. Merck has won four federal cases involving Vioxx and lost one. In state courts, the drugmaker has now won four cases and lost three. A case in New Jersey has been ordered to retrial after jurors sided with Merck.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to Know: Thursday, August 28

Five things for Pharma Marketers to Know: Thursday, ...

Human testing of GSK's Ebola virus starts next week, menopause is a costly healthcare concern, and a small conversation with pharmacists may have a big impact.

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.